Evaluation of the ratio method compared with graphical analyses for estimating nigrostriatal function in human18F-DOPA pet studies with or without carbidopa

Nuclear Medicine Communications

Volumn 14, Issue 10, 1993, Pages 862-867

  Otsuka, M ^a   Ichiya, Y ^a   Kuwabara, Y ^a   Fukumura, T ^a   Sasaki, M ^a   Masuda, K ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA; FLUORODOPA F 18; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NIGRONEOSTRIATAL SYSTEM; ORAL DRUG ADMINISTRATION; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY;

ADULT; CARBIDOPA; COMPARATIVE STUDY; CORPUS STRIATUM; DIHYDROXYPHENYLALANINE; FEMALE; FLUORINE RADIOISOTOPES; HUMAN; MALE; MIDDLE AGE; PARKINSON DISEASE; REFERENCE VALUES; SUBSTANTIA NIGRA; SUPPORT, NON-U.S. GOV'T; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0027451055     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-199310000-00005     Document Type: Article

References (17)

1. Firnou G, Sood S, Chirakal R et al. Cerebral metabolism at 6-18F-fluoro-L-3,4-dihydroxy-phenylalanine in the primate. J Neurochem 1987; 48: 1077-82.
2. Cumming P, Adams MJ, Hausser M et al. Kinetics of in vitro decarboxylation and in vivo metabolism of 2-18F- and 6-18-F-fluorodopa in the hooded rat. Biochem Pharmacol 1988; 37: 247-50.
3. Garnett ES, Firnou G, Nahmias C et al. Blood-brain barrier transport and cerebral utilization of dopa in living monkeys. Am J Physiol 1980; 238: R318-R327.
4. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3: 1-7.
5. Martin WRW, Palmer MR, Patlak CS, Caine DB. Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol 1989; 26: 535-42.
6. Tedroff J, Aquilonius S-M, Laihinen A et al. Striatal kinetics of [nC]-(+)-nomifensine and 6-[18F]fluoro-L-dopa in Parkinson's disease measured with positron emission tomography. Acta Neurol Scand 1990; 81: 24-30.
7. Huang S-C, Yu D-C, Barrio JR et al. Kinetics and modeling of L-6-[18F]fluoro-DOPA in human positron emission tomographic studies. J Cereb Blood Flow Metab 1991; 11: 898-913.
8. Boyes BE, Cumming P, Martin WRW, McGeer EG. Determination of plasma [lsF]-6-fluorodopa during positron emission tomography. Life Sci 1986; 39: 2243-52.
9. Doudet DJ, Mcl.ellan CA, Carson R et al. Distribution and kinetics of 3-0-methyl-6-[’8F]fluoro-L-DOPA in the rhesus monkey brain. J Cereb Blood Flow Metab 1991; 11: 726-34.
10. Kanno I, Miura S, Yamamoto S et al. Design and evaluation of the positron emission tomograph: HEADTOME 111. I Comput Assist Tomog 1985; 9: 931-9.
11. Otsuka M, Ichiya Y, Kuwabara Y et al. Cerebral blood flow, oxygen and glucose metabolism with PET in progressive supranuclear palsy. Ann Nucl Med 1989; 3:111-18.
12. Otsuka M, Ichiya Y, Hosokawa S et al. Striatal blood flow, glucose metabolism and,8F-Dopa uptake: difference in Parkinson's disease and atypical Parkinsonism. J Neurol Neurosurg Psychiatry 1991; 54: 898-904.
13. Martin WRW, Stoessl AJ, Adam MJ et al. Positron emission tomography in Parkinson's disease: glucose and dopa metabolism. Adv Neurol 1986; 45: 95-8.
14. Leenders KL, Palmer AJ, Quinn N et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986; 49: 853-60.
15. Brooks DJ, Ibanez V, Sawle GV et al. Differing patterns of striatal,8F-Dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28: 547-55.
16. Gjedde A, Reith J, Kuwabara H, Dyve S. Determining dopa decarboxylase activity in human brain in vivo: the complete fluoro-dopa model. J Nucl Med 1990; 31: 720.
17. Melega WP, Hoffman JM, Luxen A et al. The effect of carbidopa on the metabolism of 6-[18F] fluoro-L-dopa in rats, monkeys and humans. Life Sci 1990; 47: 149-57.